Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. NARAIN (Lucknow, India), E. Dhamija (Lucknow, India), K. Srivastava (Lucknow, India), K. Srivastava (Lucknow, India), S. Kant (Lucknow, India). Construing the role of Proteasome Accessory Factor-C in fluoroquinolone resistance in pulmonary tuberculosis. 4754

Member's Comments

No comment yet.

Related content which might interest you: Proteasome Accessory Factor-C (PafC) as a potential regulator of mycobacterial survival in multi drug-resistant tuberculosis patients Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Outcome of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Primary drug resistance in pulmonary tuberculosis Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Antibiotic resistance in pulmonary infections: mechanisms and epidemiology Source: Eur Respir Monogr 2017; 75: 21-43 Year: 2017 Role of cytokines in the immunopathogenesis of the MDR pulmonary tuberculosis Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Characteristics of the cases with primary multidrug resistance pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 A study to perceive the role and function of Proteasome Accessory Factor-C (PafC) inMycobacterium tuberculosis. Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019 Multidrug resistant pulmonary TB: Characteristics of drug resistance profiles of MBT in Ukraine Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Multi-drug resistant pulmonary tuberculosis in Belarus Source: Annual Congress 2007 - Epidemiology of various lung diseases Year: 2007 Cytokines in pathogenesis of pulmonary tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Primary drug resistance rates in pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003 Drug resistance in pulmonary tuberculosis in Turkey Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis Source: Eur Respir J 2012; 39: 1511-1519 Year: 2012 Radiologic findings of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 202s Year: 2004 Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Intravenous ozon in MDR pulmonary tuberculosis Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Mycobacterium tuberculosis Cording in Alveolar Macrophages of Tuberculosis Patients and Mycobacterial Virulence Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections Year: 2017